Ignite Creation Date:
2025-12-24 @ 5:26 PM
Ignite Modification Date:
2026-03-28 @ 11:33 AM
Study NCT ID:
NCT02720068
Status:
COMPLETED
Last Update Posted:
2025-05-30
First Post:
2016-03-22
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Neoplasms | View |